Suspension and Resumption - Duku Culture, Aolian Electronics, and Yichang Technology are planning a change in control, leading to stock suspension [1] - Xusheng Group's actual controller has changed to the Guangzhou Municipal Government, resulting in stock resumption [2] Share Buyback - Nanshan Aluminum plans to repurchase shares worth between 300 million to 600 million yuan for cancellation [3] Mergers and Acquisitions - China Nonferrous Metal Industry's subsidiary intends to acquire 99.9% of Raura Company for 106 million USD, with Raura's main assets being the Raura zinc polymetallic mine and a hydropower station in Peru [4] - Lingyi Technology plans to acquire 35% of Limin Da for 875 million yuan, focusing on advanced thermal management solutions for enterprise-level servers [4] External Investment and Daily Operations - Ultrasonic Electronics plans to invest 1 billion yuan in upgrading high-performance HDI printed circuit board production [5] - Nanya New Materials aims to raise no more than 900 million yuan for AI-powered high-frequency copper-clad laminate R&D and industrialization projects [6] - Lingyun Optical's subsidiary intends to act as a cornerstone investor in the IPO of Zhipu on the Hong Kong Stock Exchange [7] - Tongyu Communication's subsidiary plans to increase capital and introduce investors to enhance its satellite communication product development and operational funding [7] - Sanli Pharmaceutical intends to acquire the HXW2324 compound and related patents from Hainan University for developing new Alzheimer's treatment candidates [7] - Yongding Co., Ltd.'s optical chip subsidiary plans to increase capital and introduce external investors such as Cambridge Technology [8] - Xiangyu Medical's brain-computer interface products have entered over 500 top-tier hospitals, with a target of over 700 by the upcoming Spring Festival [9] - Dingyang Technology has released a 20 GHz high-bandwidth digital oscilloscope, the SDS8204A [10] - Suzhou Tianmai plans to establish a joint venture for server liquid cooling business [11] - Zhuoran Co., Ltd.'s subsidiary signed a supplementary agreement for a 4.033 billion yuan contract related to a biodegradable polyester project [11] - Ningbo Huaxiang's subsidiary signed a strategic cooperation agreement with Dahuang Robot for the development of specific six-degree-of-freedom dexterous hand products [12] - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker "Kaituo" in Dalian [13] - Xin Nuo Wei is establishing a joint venture focused on GLP-1 target-related products [14] - New Construction Co., Ltd. signed a framework cooperation agreement for an integrated energy security project at the Duolong Copper Mine in Tibet [15] - Xiechuang Data signed a strategic cooperation agreement with Puyin Financial Leasing, aiming for a cooperation scale of 2 billion yuan in computing power financing leasing [15] Performance Changes - Sanhua Intelligent Control expects a net profit of 3.874 billion to 4.649 billion yuan for 2025, representing a year-on-year growth of 25% to 50%, driven by its leading position in refrigeration and air conditioning components and expansion in the automotive parts sector [16]

Group 1 - Rongchang Biotech plans to repurchase shares worth between 20 million and 40 million yuan, with a maximum price of 95 yuan per share, aiming to buy back approximately 21,050 to 42,110 shares, representing about 0.04% to 0.07% of total share capital [1] - Nanya New Materials intends to raise no more than 900 million yuan through a private placement for AI computing power-based high-frequency high-speed copper-clad laminate R&D and working capital [2] - Xiechuang Data has signed a strategic cooperation agreement with Ping An Financial Leasing, aiming for a cooperation scale of 2 billion yuan over three years [3] Group 2 - Chuangshi Technology's controlling shareholder is under investigation and has been placed under detention, having resigned from all positions in the company [4] - Deep Kangjia A has reported overdue shareholder loans to Yikang Technology and Chuzhou Kangxin, totaling approximately 233 million yuan and 395 million yuan respectively, due to repayment issues [5] - Ningbo Yuanyang announced the resignation of two directors due to work adjustments [6] Group 3 - China Merchants Energy has delivered the world's first methanol dual-fuel VLCC oil tanker, with 15 oil tanker orders in hand [7] - Tianyu Co., Ltd. has received a drug registration certificate for hydrochloride trazodone tablets, which are used for treating depression [8] - Haizheng Pharmaceutical has received FDA approval for clinical trials of HS387 tablets for treating advanced solid tumors [9] Group 4 - Warner Pharmaceuticals has obtained a drug registration certificate for isoproterenol hydrochloride injection, used for treating shock and complete atrioventricular block [10] - Hekang New Energy's subsidiary received a government subsidy of 1.5 million yuan, which accounts for 14.57% of the company's latest audited net profit [11] - Duku Culture is planning a change in company control, with stock suspension expected for no more than two trading days [12] Group 5 - Haisco has received acceptance for an IND application for HSK46575 tablets for prostate cancer treatment [13] - *ST Xinyan is executing a capital reserve transfer to increase share capital, resulting in a stock suspension [14] - Nanjing Public Utilities is transferring a 45% stake in a subsidiary for 23.6443 million yuan [15] Group 6 - Action Education plans to repurchase shares worth between 20 million and 25 million yuan, with a maximum price of 45 yuan per share [16] - Bai'ao Tai has received government subsidies totaling 29 million yuan [18] - Weisi Medical intends to sell assets worth 119 million yuan, expecting a profit impact of approximately 10 million yuan [19] Group 7 - Tongyu Communications plans to increase capital by 10 million yuan to introduce investment from Wuchuang Institute [20] - Dongtu Technology's subsidiary is introducing strategic investor Guofeng Investment Fund with a capital increase of 11 million yuan [21] - China General Nuclear Power Technology's shareholder is facing a judicial auction of 2.91% of the company's shares [22] Group 8 - Nanshan Aluminum plans to repurchase shares worth between 300 million and 600 million yuan, with a maximum price of 7.52 yuan per share [23] - Yipin Hong's controlling shareholder has committed to transferring 9.07% equity in Arthrosi without compensation [24] - Sanli Pharmaceutical has signed a technology transfer contract worth 200 million yuan with Hainan University [25] Group 9 - Xin Nuo Wei plans to jointly invest 450 million yuan with Zhongqi Pharmaceutical to establish a joint venture focusing on innovative metabolic drugs [26] - Li Qun Co. has been approved to issue 1 billion yuan in medium-term notes to optimize debt structure and supplement working capital [27] - Dongfang Ocean's subsidiary has received a medical device registration certificate for a procalcitonin test kit [28] Group 10 - Tibet Mining's chairman has resigned due to work adjustments [29] - Wantai Biological's subsidiary has been shortlisted for a national immunization program vaccine procurement project, with a bid price of 27.5 yuan [30] - Xingfu Blue Sea has appointed Zhang Chen as the new deputy general manager [31] Group 11 - Changyuan Donggu has elected Li Yixuan as the vice chairman of the board [32] - Ningbo Huaxiang's subsidiary has signed a strategic cooperation agreement with Dahuang Robotics for collaboration in humanoid robot development [33] - Yongda Co. has been pre-selected for a procurement project worth approximately 350 million yuan [34] Group 12 - Fuan Pharmaceutical's subsidiary has received a drug registration certificate for hydrochloride trazodone tablets [35] - Nanjing Food reported a 71.03% year-on-year decrease in net profit for November due to rising raw material costs [36] - Changqing Technology's special polymer monomer project has commenced production [37]

Core Viewpoint - The announcement reveals that XinNuoWei plans to establish a joint venture with Zhongqi Pharmaceutical, focusing on the development and commercialization of innovative metabolic drugs, particularly targeting GLP-1 related products [1] Group 1: Joint Venture Details - XinNuoWei will invest 157.5 million yuan, holding a 35% stake in the joint venture, while Zhongqi Pharmaceutical will contribute 292.5 million yuan for a 65% stake [1] - The total investment for the joint venture is set at 450 million yuan [1] Group 2: Business Focus - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs, targeting areas such as overweight/obesity and type 2 diabetes [1] - The company plans to develop new drug formulations and expand indications continuously [1] Group 3: Product Pipeline - The joint venture will take over all GLP-1 related product pipelines from Shijiazhuang Pharmaceutical Group, including those in preclinical research, clinical stages, and those submitted for market approval [1] - The company aims to enhance its product matrix through various methods, including independent development, rights acquisition, and pipeline introduction [1]

Core Viewpoint - The company plans to establish a joint venture with Zhongqi Pharmaceutical Technology Co., Ltd. with a total investment of 450 million RMB, focusing on the development and commercialization of innovative metabolic drugs targeting GLP-1 [1] Group 1: Joint Venture Details - The company will contribute 157 million RMB, representing 35% of the registered capital [1] - Zhongqi Pharmaceutical will invest 292 million RMB, holding 65% of the registered capital [1] - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs [1] Group 2: Transaction Classification - This transaction is classified as a related party transaction and does not constitute a major asset reorganization [1]

Core Viewpoint - The establishment of a joint venture between XinNuoWei and Zhongqi Pharmaceutical aims to enhance the company's position in the innovative biopharmaceutical sector, particularly focusing on GLP-1 target products, driven by increasing health awareness and medical spending in China [1][2] Group 1 - The joint venture will be funded with a total investment of 45 million RMB, with XinNuoWei contributing 15.75 million RMB (35% ownership) and Zhongqi Pharmaceutical contributing 29.25 million RMB (65% ownership) [1] - The joint venture will focus on the research, industrialization, and commercialization of innovative metabolic drugs, particularly targeting obesity and type 2 diabetes [1] - The joint venture will take over all GLP-1 related product pipelines from Shiyao Group, including preclinical, clinical, and market application stages, and will explore various methods to expand its product pipeline [2]

Group 1 - The core point of the article is that XinNuoWei (300765) announced plans to establish a joint venture with Zhongqi Pharmaceutical, contributing a total of 450 million yuan, with XinNuoWei investing 158 million yuan for a 35% stake in the new company [1] - The joint venture will focus on the research, industrialization, and commercialization of innovative metabolic drugs, particularly targeting GLP-1 related products [1] - The new company will take over the entire pipeline of GLP-1 related products from Shiyao Group Co., Ltd., which includes treatments for overweight/obesity and type 2 diabetes, and will continue to develop new formulations and expand indications [1]

每经头条（nbdtoutiao）——新能源重卡爆单了，11月销量同比增长178%！两班倒都供不应求，客户直 接进厂催单，这情景十年难遇 （记者 曾健辉） 每经AI快讯，新诺威（SZ 300765，收盘价：35.62元）12月22日晚间发布公告称，石药创新制药股份有 限公司董事会于本日（2025年12月22日）收到公司董事CAI LEI（蔡磊）先生的书面辞职报告。CAI LEI先生申请辞任公司董事职务，辞任后不再担任公司任何职务。 2024年1至12月份，新诺威的营业收入构成为：功能食品及原料行业占比92.91%，生物制药行业占比 4.43%，其他业务占比2.66%。 截至发稿，新诺威市值为500亿元。 ...

新诺威12月22日公告，公司董事会当天收到公司董事 CAI LEI（蔡磊）的书面辞职报告，蔡磊因工作变 动原因申请辞任公司董事职务，辞任后不再担任公司任何职务。蔡磊的辞职报告自送达董事会时生效。 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事离任情况 证券代码：300765 证券简称：新诺威 公告编号：2025-100 石药创新制药股份有限公司 关于董事离任的公告 CAI LEI（蔡磊）先生的辞职报告。 特此公告。 石药创新制药股份有限公司 董事会 2025 年 12 月 22 日 1 石药创新制药股份有限公司（以下简称"公司"）董事会于本日（2025 年 12 月 22 日）收到公司董事 CAI LEI（蔡磊）先生的书面辞职报告，具体情况如下： 因工作变动原因，CAI LEI（蔡磊）先生申请辞任公司董事职务,辞任后不再 担任公司任何职务。CAI LEI（蔡磊）先生的原定任期届满之日为 2026 年 4 月 6 日，其辞任未导致公司董事会人数低于法定最低人数，其辞职报告自送达董事会 时生效。截至本公告披露之日，CAI LEI（蔡磊）先生未直接持有公司股份。辞 去相关职务后，CAI LEI（蔡磊）先生将继续严格遵守国家相关法律、法规及《上 市公司股东、董监高减持股份的若干规定》《深圳证券交易所上市公司股东及董 事、监事、高级管理人员减持股份实施 ...

石药创新制药股份有限公司（以下简称"公司"或"上市公司"）第六届董事会 第二十九次会议（以下简称"本次会议"）于 2025 年 12 月 22 日在公司会议室以 现场加通讯表决相结合的方式召开，会议通知于 2025 年 12 月 19 日以专人送出、 电话通知等方式送达全体董事。 会议由公司董事长姚兵先生主持，公司高级管理人员列席了本次会议。本次 会议应出席董事人数 9 人，实际出席董事人数 9 人。出席董事资格、人数以及召 集、召开程序等均符合《中华人民共和国公司法》等法律法规和《石药创新制药 股份有限公司章程》的规定，本次会议合法有效。 证券代码：300765 证券简称：新诺威 公告编号：2025-098 石药创新制药股份有限公司 第六届董事会第二十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 表决结果：同意 6 票，反对 0 票，弃权 0 票，回避 3 票。 三、备查文件 1、石药创新制药股份有限公司第六届董事会第二十九次会议决议； 二、董事会会议审议情况 经与会董事充分讨论，本次会议审议并通过了如下议案： 1 ...